Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Nuclear Receptor Regulation of Aquaglyceroporins in Metabolic Organs.

Tardelli M, Claudel T, Bruschi FV, Trauner M.

Int J Mol Sci. 2018 Jun 15;19(6). pii: E1777. doi: 10.3390/ijms19061777. Review.

2.

Thyroid hormone receptor β1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice.

Gautherot J, Claudel T, Cuperus F, Fuchs CD, Falguières T, Trauner M.

J Lipid Res. 2018 Sep;59(9):1610-1619. doi: 10.1194/jlr.M084145. Epub 2018 Jun 12.

PMID:
29895698
3.

PNPLA3 expression and its impact on the liver: current perspectives.

Bruschi FV, Tardelli M, Claudel T, Trauner M.

Hepat Med. 2017 Nov 6;9:55-66. doi: 10.2147/HMER.S125718. eCollection 2017. Review.

4.

AQP3 is regulated by PPARγ and JNK in hepatic stellate cells carrying PNPLA3 I148M.

Tardelli M, Bruschi FV, Claudel T, Moreno-Viedma V, Halilbasic E, Marra F, Herac M, Stulnig TM, Trauner M.

Sci Rep. 2017 Nov 7;7(1):14661. doi: 10.1038/s41598-017-14557-9.

5.

FXR controls CHOP expression in steatohepatitis.

Fuchs CD, Claudel T, Scharnagl H, Stojakovic T, Trauner M.

FEBS Lett. 2017 Oct;591(20):3360-3368. doi: 10.1002/1873-3468.12845. Epub 2017 Oct 11.

6.

Adiponectin regulates AQP3 via PPARα in human hepatic stellate cells.

Tardelli M, Claudel T, Bruschi FV, Moreno-Viedma V, Trauner M.

Biochem Biophys Res Commun. 2017 Aug 12;490(1):51-54. doi: 10.1016/j.bbrc.2017.06.009. Epub 2017 Jun 5.

7.

Impact of higher-order heme degradation products on hepatic function and hemodynamics.

Seidel RA, Claudel T, Schleser FA, Ojha NK, Westerhausen M, Nietzsche S, Sponholz C, Cuperus F, Coldewey SM, Heinemann SH, Pohnert G, Trauner M, Bauer M.

J Hepatol. 2017 Aug;67(2):272-281. doi: 10.1016/j.jhep.2017.03.037. Epub 2017 Apr 12.

8.

Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.

Steinacher D, Claudel T, Trauner M.

Dig Dis. 2017;35(3):282-287. doi: 10.1159/000454853. Epub 2017 Mar 1. Review.

PMID:
28249257
9.

The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells.

Bruschi FV, Claudel T, Tardelli M, Caligiuri A, Stulnig TM, Marra F, Trauner M.

Hepatology. 2017 Jun;65(6):1875-1890. doi: 10.1002/hep.29041. Epub 2017 Apr 18.

PMID:
28073161
10.

Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.

Trauner M, Halilbasic E, Claudel T, Steinacher D, Fuchs C, Moustafa T, Pollheimer M, Krones E, Kienbacher C, Traussnigg S, Kazemi-Shirazi L, Munda P, Hofer H, Fickert P, Paumgartner G.

Dig Dis. 2015;33(3):433-9. doi: 10.1159/000371904. Epub 2015 May 27. Review.

PMID:
26045280
11.

PAK1 modulates a PPARγ/NF-κB cascade in intestinal inflammation.

Dammann K, Khare V, Lang M, Claudel T, Harpain F, Granofszky N, Evstatiev R, Williams JM, Pritchard DM, Watson A, Gasche C.

Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2349-60. doi: 10.1016/j.bbamcr.2015.05.031. Epub 2015 May 31.

12.

Micro RNA-124a regulates lipolysis via adipose triglyceride lipase and comparative gene identification 58.

Das SK, Stadelmeyer E, Schauer S, Schwarz A, Strohmaier H, Claudel T, Zechner R, Hoefler G, Vesely PW.

Int J Mol Sci. 2015 Apr 16;16(4):8555-68. doi: 10.3390/ijms16048555.

13.

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.

Mueller M, Thorell A, Claudel T, Jha P, Koefeler H, Lackner C, Hoesel B, Fauler G, Stojakovic T, Einarsson C, Marschall HU, Trauner M.

J Hepatol. 2015 Jun;62(6):1398-404. doi: 10.1016/j.jhep.2014.12.034. Epub 2015 Jan 21.

14.

24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.

Sombetzki M, Fuchs CD, Fickert P, Österreicher CH, Mueller M, Claudel T, Loebermann M, Engelmann R, Langner C, Sahin E, Schwinge D, Guenther ND, Schramm C, Mueller-Hilke B, Reisinger EC, Trauner M.

J Hepatol. 2015 Apr;62(4):871-8. doi: 10.1016/j.jhep.2014.11.020. Epub 2014 Nov 21.

15.

The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism.

Demetz E, Schroll A, Auer K, Heim C, Patsch JR, Eller P, Theurl M, Theurl I, Theurl M, Seifert M, Lener D, Stanzl U, Haschka D, Asshoff M, Dichtl S, Nairz M, Huber E, Stadlinger M, Moschen AR, Li X, Pallweber P, Scharnagl H, Stojakovic T, März W, Kleber ME, Garlaschelli K, Uboldi P, Catapano AL, Stellaard F, Rudling M, Kuba K, Imai Y, Arita M, Schuetz JD, Pramstaller PP, Tietge UJF, Trauner M, Norata GD, Claudel T, Hicks AA, Weiss G, Tancevski I.

Cell Metab. 2014 Nov 4;20(5):787-798. doi: 10.1016/j.cmet.2014.09.004.

16.

Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients.

Wree A, Schlattjan M, Bechmann LP, Claudel T, Sowa JP, Stojakovic T, Scharnagl H, Köfeler H, Baba HA, Gerken G, Feldstein AE, Trauner M, Canbay A.

Metabolism. 2014 Dec;63(12):1542-52. doi: 10.1016/j.metabol.2014.09.001. Epub 2014 Sep 6.

PMID:
25267016
17.

Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD.

Fuchs CD, Claudel T, Trauner M.

Trends Endocrinol Metab. 2014 Nov;25(11):576-85. doi: 10.1016/j.tem.2014.08.001. Epub 2014 Aug 30. Review.

PMID:
25183341
18.

Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis.

Stiedl P, McMahon R, Blaas L, Stanek V, Svinka J, Grabner B, Zollner G, Kessler SM, Claudel T, Müller M, Mikulits W, Bilban M, Esterbauer H, Eferl R, Haybaeck J, Trauner M, Casanova E.

Hepatology. 2015 Feb;61(2):613-26. doi: 10.1002/hep.27408.

19.

Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH).

Jha P, Knopf A, Koefeler H, Mueller M, Lackner C, Hoefler G, Claudel T, Trauner M.

Biochim Biophys Acta. 2014 Jul;1842(7):959-70. doi: 10.1016/j.bbadis.2014.02.012. Epub 2014 Mar 1.

20.

The role of canalicular ABC transporters in cholestasis.

Cuperus FJ, Claudel T, Gautherot J, Halilbasic E, Trauner M.

Drug Metab Dispos. 2014 Apr;42(4):546-60. doi: 10.1124/dmd.113.056358. Epub 2014 Jan 28. Review.

PMID:
24474736
21.

Bile acid-mediated control of liver triglycerides.

Fuchs C, Claudel T, Trauner M.

Semin Liver Dis. 2013 Nov;33(4):330-42. doi: 10.1055/s-0033-1358520. Epub 2013 Nov 12. Review.

PMID:
24222091
22.

Editorial for 'randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis'.

Stojakovic T, Claudel T, Trauner M.

Liver Int. 2014 Mar;34(3):328-9. doi: 10.1111/liv.12359. No abstract available.

PMID:
24134772
23.

Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia.

Jha P, Claudel T, Baghdasaryan A, Mueller M, Halilbasic E, Das SK, Lass A, Zimmermann R, Zechner R, Hoefler G, Trauner M.

Hepatology. 2014 Mar;59(3):858-69. doi: 10.1002/hep.26732. Epub 2014 Jan 28.

PMID:
24002947
24.

The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism.

Huang J, Das SK, Jha P, Al Zoughbi W, Schauer S, Claudel T, Sexl V, Vesely P, Birner-Gruenberger R, Kratky D, Trauner M, Hoefler G.

Biochim Biophys Acta. 2013 Oct;1831(10):1555-65. doi: 10.1016/j.bbalip.2013.04.012. Epub 2013 Apr 26.

25.

Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice.

Gautier T, de Haan W, Grober J, Ye D, Bahr MJ, Claudel T, Nijstad N, Van Berkel TJ, Havekes LM, Manns MP, Willems SM, Hogendoorn PC, Lagrost L, Kuipers F, Van Eck M, Rensen PC, Tietge UJ.

J Lipid Res. 2013 Aug;54(8):2195-205. doi: 10.1194/jlr.M038141. Epub 2013 Apr 25.

26.

Adiponectin, bile acids, and burnt-out nonalcoholic steatohepatitis: new light on an old paradox.

Claudel T, Trauner M.

Hepatology. 2013 Jun;57(6):2106-9. doi: 10.1002/hep.26340. No abstract available.

PMID:
23447428
27.

Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice.

Chennamsetty I, Kostner KM, Claudel T, Vinod M, Frank S, Weiss TS, Trauner M, Kostner GM.

J Lipid Res. 2012 Nov;53(11):2405-12. doi: 10.1194/jlr.M029769. Epub 2012 Aug 28.

28.

Bile acid transporters and regulatory nuclear receptors in the liver and beyond.

Halilbasic E, Claudel T, Trauner M.

J Hepatol. 2013 Jan;58(1):155-68. doi: 10.1016/j.jhep.2012.08.002. Epub 2012 Aug 8. Review.

29.

Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice.

Fuchs CD, Claudel T, Kumari P, Haemmerle G, Pollheimer MJ, Stojakovic T, Scharnagl H, Halilbasic E, Gumhold J, Silbert D, Koefeler H, Trauner M.

Hepatology. 2012 Jul;56(1):270-80. doi: 10.1002/hep.25601. Epub 2012 May 29.

PMID:
22271167
30.

FGF19 signaling cascade suppresses APOA gene expression.

Chennamsetty I, Claudel T, Kostner KM, Trauner M, Kostner GM.

Arterioscler Thromb Vasc Biol. 2012 May;32(5):1220-7. doi: 10.1161/ATVBAHA.111.243055. Epub 2012 Jan 19.

PMID:
22267484
31.

Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output.

Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, Vecchiotti S, Gonzalez FJ, Schoonjans K, Strazzabosco M, Fickert P, Trauner M.

Hepatology. 2011 Oct;54(4):1303-12. doi: 10.1002/hep.24537.

32.

Farnesoid X receptor represses hepatic human APOA gene expression.

Chennamsetty I, Claudel T, Kostner KM, Baghdasaryan A, Kratky D, Levak-Frank S, Frank S, Gonzalez FJ, Trauner M, Kostner GM.

J Clin Invest. 2011 Sep;121(9):3724-34. doi: 10.1172/JCI45277. Epub 2011 Aug 1.

33.

Targeting nuclear bile acid receptors for liver disease.

Trauner M, Baghdasaryan A, Claudel T, Fickert P, Halilbasic E, Moustafa T, Zollner G.

Dig Dis. 2011;29(1):98-102. doi: 10.1159/000324141. Epub 2011 Jun 17. Review.

PMID:
21691114
34.

Proline- and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor alpha (PPARalpha) activity.

Gachon F, Leuenberger N, Claudel T, Gos P, Jouffe C, Fleury Olela F, de Mollerat du Jeu X, Wahli W, Schibler U.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4794-9. doi: 10.1073/pnas.1002862108. Epub 2011 Mar 7.

35.

Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease.

Claudel T, Zollner G, Wagner M, Trauner M.

Biochim Biophys Acta. 2011 Aug;1812(8):867-78. doi: 10.1016/j.bbadis.2010.12.021. Epub 2010 Dec 29. Review.

36.

Plasma bile acids are not associated with energy metabolism in humans.

Brufau G, Bahr MJ, Staels B, Claudel T, Ockenga J, Böker KH, Murphy EJ, Prado K, Stellaard F, Manns MP, Kuipers F, Tietge UJ.

Nutr Metab (Lond). 2010 Sep 3;7:73. doi: 10.1186/1743-7075-7-73.

37.

Bile acids as regulators of hepatic lipid and glucose metabolism.

Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M.

Dig Dis. 2010;28(1):220-4. doi: 10.1159/000282091. Epub 2010 May 7. Review.

PMID:
20460915
38.

New insights into autoimmune cholangitis through animal models.

Trauner M, Fickert P, Baghdasaryan A, Claudel T, Halilbasic E, Moustafa T, Wagner M, Zollner G.

Dig Dis. 2010;28(1):99-104. doi: 10.1159/000282072. Epub 2010 May 7. Review.

PMID:
20460897
39.

Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation.

Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüringer A, Leski K, Fickert P, Karpen SJ, Trauner M.

Gut. 2010 Apr;59(4):521-30. doi: 10.1136/gut.2009.186528.

40.

Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment.

Stojakovic T, Claudel T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Sourij H, Stauber RE, Winkler K, März W, Wascher TC, Trauner M.

Atherosclerosis. 2010 Mar;209(1):178-83. doi: 10.1016/j.atherosclerosis.2009.08.052. Epub 2009 Sep 6.

PMID:
19782361
41.

REV-ERBalpha participates in circadian SREBP signaling and bile acid homeostasis.

Le Martelot G, Claudel T, Gatfield D, Schaad O, Kornmann B, Lo Sasso G, Moschetta A, Schibler U.

PLoS Biol. 2009 Sep;7(9):e1000181. doi: 10.1371/journal.pbio.1000181. Epub 2009 Sep 1.

42.

Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice.

Baghdasaryan A, Fickert P, Fuchsbichler A, Silbert D, Gumhold J, Hörl G, Langner C, Moustafa T, Halilbasic E, Claudel T, Trauner M.

Liver Int. 2008 Aug;28(7):948-58. doi: 10.1111/j.1478-3231.2008.01758.x. Epub 2008 Apr 11.

PMID:
18410282
43.

Crosstalk between xenobiotics metabolism and circadian clock.

Claudel T, Cretenet G, Saumet A, Gachon F.

FEBS Lett. 2007 Jul 31;581(19):3626-33. Epub 2007 Apr 17. Review.

44.

High frequency of a retinoid X receptor gamma gene variant in familial combined hyperlipidemia that associates with atherogenic dyslipidemia.

Nohara A, Kawashiri MA, Claudel T, Mizuno M, Tsuchida M, Takata M, Katsuda S, Miwa K, Inazu A, Kuipers F, Kobayashi J, Koizumi J, Yamagishi M, Mabuchi H.

Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):923-8. Epub 2007 Feb 1.

PMID:
17272748
45.

The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.

Claudel T, Staels B, Kuipers F.

Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2020-30. Epub 2005 Jul 21. Review.

PMID:
16037564
46.

The Farnesoid X Receptor (FXR) as modulator of bile acid metabolism.

Kuipers F, Claudel T, Sturm E, Staels B.

Rev Endocr Metab Disord. 2004 Dec;5(4):319-26. Review. No abstract available.

PMID:
15486464
47.

The farnesoid X receptor: a novel drug target?

Claudel T, Sturm E, Kuipers F, Staels B.

Expert Opin Investig Drugs. 2004 Sep;13(9):1135-48. Review.

PMID:
15330745
48.

The farnesoid X receptor induces very low density lipoprotein receptor gene expression.

Sirvent A, Claudel T, Martin G, Brozek J, Kosykh V, Darteil R, Hum DW, Fruchart JC, Staels B.

FEBS Lett. 2004 May 21;566(1-3):173-7.

49.

Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.

Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, Fruchart JC, Gonzalez FJ, Staels B.

Gastroenterology. 2003 Aug;125(2):544-55.

PMID:
12891557
50.

FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity.

Barbier O, Torra IP, Sirvent A, Claudel T, Blanquart C, Duran-Sandoval D, Kuipers F, Kosykh V, Fruchart JC, Staels B.

Gastroenterology. 2003 Jun;124(7):1926-40.

PMID:
12806625

Supplemental Content

Loading ...
Support Center